Events

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

A dynamic environment for clinical research is one of the most important cornerstones in ensuring future growth for the Life Science community in Medicon Valley. Clinical development provide new research, knowledge and skills and give patients access to new and often life-saving, medical treatment. However, the clinical research activity has faced dramatic falls in both […]

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

Medicon Valley Alliance in collaboration with ICON plc invites you to join leading industry experts on biomarker research for a unique, dynamic and interactive evening. Science after Hours is a “moving round table” networking event where you can learn and engage with leading biomarker experts and industry colleagues about compelling scientific insights on the use […]

11 October 2012 /  Lund / Sweden Medicon Valley Alliance has partnered up with CREATE Health and presents the first Cancer Crosslinks Sweden. By bringing together researchers from healthcare providers, academia, and industry with representatives from regulatory units in a one-day meeting, we want to start an interdisciplinary discussion that could lead to new partnerships […]

Learn about MVA, our networks and our initiatives. Get an insight into what value your organization can gain from your MVA membership. Understand how MVA works to maintain and develop the attractiveness of Medicon Valley. 4 October 2012 / Ørestad / Denmark Join us at the MVA introductory meeting and learn more about the many […]

The Nordic arena for early clinical trials attracts pharmaceutical companies from all over the world. What they seek is high quality trials performed by high performing sites. What can the Nordic countries provide and how can companies within the Medicon Valley make best use of the expertise available right on our doorstep? This seminar aims […]

13-14 September 2012 / Lund / Sweden Workshop at INNOVATION IN MIND: How to strengthen life science in Medicon Valley via cross sector collaboration? Organized by Annika Antius (Region Skåne), Susanna Dahlgren (Medicon Valley Alliance), Lovisa Sunesson (Invest in Skåne). Venue: Palaestra lower. INNOVATION IN MIND is an annual event aimed at people who are […]

IPR rules and issues in relation to the Korean market – is patenting different in Korea, compared to Europe and USA? Yes – there are differences in legislation and practices in addition to cultural differences, which together may lead to a different outcome in the patent application process in Korea compared to Europe or America. […]

15 June 2012 / Lund / Sweden (8:00 – 16:00) Nordic Journal of Chemistry & Biotechnology/Kemivärlden Biotech med Kemisk Tidskrift, Medicon Valley Alliance, and MerckMillipore are, in collaboration, organizing an important networking event. The speakers will discuss current issues in drug formulation and QA. The seminar will be held in English and will feature about 15 exhibitors […]

Are you looking to build strong life science relations in the US, Japan or South Korea? Now is your chance to take action! Our ambassadors are in Denmark and Sweden in June and are looking forward to meeting you. 4–8 June: Thomas Jonsson, Life Science Ambassador to Japan and South Korea is in Medicon Valley 11–15 […]

At this networking meeting, patent experts from Høiberg A/S will talk about why it is still possible to patent personalized medicine and diagnostic methods following the recent decision (Mayo vs. Prometheus) from the US Supreme Court? You will be guide through the aftermath of the Prometheus decision. Additionally the meeting will focus on strategies to […]

At this networking meeting, patent experts from Høiberg A/S will talk about why it is still possible to patent personalized medicine and diagnostic methods following the recent decision (Mayo vs. Prometheus) from the US Supreme Court? You will be guide through the aftermath of the Prometheus decision. Additionally the meeting will focus on strategies to […]

Members of Medicon Valley Alliance are invited to attend the Ordinary General Meeting 2012. Agenda Election of chairperson. The Board of Directors’ report on MVA’s activities in the past year. Presentation of the annual report, including auditor’s report, adoption of the annual report and the establishment of the Board of Director’s remuneration. Resolution on the […]

17 April 2012 / Ørestad / Denmark Medicon Valley Alliance in cooperation with DNB invites you to participate in a network meeting on how to attract investors and industry partners to a life science company. At the meeting you will also have the opportunity to present you technology / business plan to any of the […]

Hear about MVA and our networks and initiatives. Get an insight into what value your organization gains from your membership of MVA.  Learn more about how MVA works to maintain and develop the attractiveness of Medicon Valley. 22 March 2012 / Ørestad / Denmark Join other members and non-members at the introductory meeting to MVA […]

This seminar will address several of today’s key challenges in drug development leading up to clinical proof of concept. The agenda brings together a panel of speakers from academia, pharmaceutical companies and solution providers to discuss key issues from formulation design right through to effective clinical trial planning. The final session w ill discuss how […]

Organotypic 3D-cell-culture systems are implemented at various stages in the compound development process for de-risking new drug candidates and can provide a wealth of meaningful efficacy and toxicology data. A growing list of publications confirms the striking similarities of these systems to in vivo tissue, clearly underlining their high potential value to the pharmaceutical industry. […]